Ye Zhang

Mrs. Ye Zhang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YMYu Meng
Yu Meng
QDQian Deng
Qian Deng
YZYe Zhang
Ye Zhang
FWFang Wei
Fang Wei
JWJun Wu
Jun Wu
HYHaijiao Yan
Haijiao Yan
Background/Objectives: Pancreatic cancer (PC) remains one of the deadliest malignancies, with challenges that hinder early detection and few actionable molecular targets. In this study, we aimed to identify biomarkers predictive of PC to support its diagnosis and treatment. Methods: Proteins from formalin-fixed, paraffin-embedded pooled samples of PC (n = 15; 5 pools) and chronic pancreatitis (n = 10; 5 pools) tissues were analyzed via label-free quantitative proteomics using liquid chromatography-tandem mass spectrometry. Immunohistochemistry (IHC) was performed on PC tissue microarrays to assess S100 calcium-binding protein P (S100P) and cathepsin E (CTSE) expression (IHC evaluable pairs: n = 78 for S100P; n = 82 for CTSE). Transwell invasion assays were conducted to evaluate the effects of these proteins on PC cell invasiveness, and Western blotting was used to validate protein expression and elucidate associated molecular mechanisms. Results: Both S100P and CTSE were overexpressed in PC tissues compared with those in adjacent normal tissues. Elevated S100P expression correlated with poor prognosis, whereas higher CTSE expression predicted favorable outcomes; both served as independent prognostic factors in PC. Functionally, S100P promoted PC cell invasion, whereas CTSE suppressed it. Mechanistically, both proteins appeared to regulate epithelial–mesenchymal transition (EMT) and invasive capacity through activation or inhibition of the phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT) signaling pathway. Conclusions: Elevated expression of S100P and CTSE in PC tissues serves as independent indicators in our model of patient survival. Both proteins regulate EMT and invasion, potentially via the PI3K–AKT pathway, and hold significant promise as prognostic biomarkers and therapeutic targets in PC.

3 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YMYu Meng
Yu Meng
FWFang Wei
Fang Wei
YZYe Zhang
Ye Zhang
WHWenting He
Wenting He
HYHaijiao Yan
Haijiao Yan
JWJun Wu
Jun Wu
Cholangiocarcinoma (CCA) is an aggressive tumor that originates from the epithelial cells of the bile duct and has the ability to metastasize to the liver or lymph nodes at an early stage. CCA metastasis represents a complex, multi-stage cascade process. Among these stages, the acquisition of invasiveness by CCA cells is a critical prerequisite for metastatic progression. Elucidating the molecular mechanisms driving CCA cell invasiveness is critical for advancing our knowledge in this field. Emerging evidence highlights the critical role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). These molecules orchestrate key processes such as the epithelial–mesenchymal transition (EMT), as well as the migration and invasion of CCA cells. Collectively, these processes ultimately drive tumor progression. This review comprehensively synthesizes the expression, biogenesis, interactions, signaling pathways, and functional mechanisms of ncRNAs in the invasiveness of CCA. Furthermore, the review discusses potential clinical applications of ncRNAs, including their roles as diagnostic tools, therapeutic targets, and prognostic markers. These investigations offer novel insights and evidence for identifying early metastasis in CCA, developing specific therapeutic strategies, and enhancing drug resistance.

26 May 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LCLei Cao
Lei Cao
JHJunxia Hu
Junxia Hu
XMXueyuan Mao
Xueyuan Mao
YXYinggang Xu
Yinggang Xu
WMWenjing Ma
Wenjing Ma
XZXiangxin Zheng
Xiangxin Zheng
Background: Malignant phyllodes tumors (MPTs) of the breast are rare fibroepithelial neoplasms characterized by aggressive clinical behavior and limited evidence guiding systemic therapy in the metastatic setting. Immune checkpoint inhibitors (ICIs) have demonstrated activity in several sarcoma subtypes; however, their role in MPTs of the breast remains poorly defined. Case presentation: A 53-year-old female patient underwent modified radical mastectomy for a rapidly enlarging left breast mass. Pathology revealed a 16.0 × 15.0 × 9.5 cm malignant phyllodes tumor with lymphovascular invasion (pT4N0). Despite the presence of an 8-mm pulmonary nodule at baseline, multiple bilateral lung metastases developed shortly after surgery. Following eight cycles of ifosfamide plus epirubicin chemotherapy, tumor burden was reduced by more than 90%. The patient subsequently received anlotinib as maintenance therapy; four months later, new hepatic and colorectal metastases emerged while the pulmonary lesions remained stable. Second-line sintilimab-based combination therapy achieved a marked partial response, with significant regression of the abdominal lesions, liquefactive necrosis of the hepatic metastases, and complete relief of abdominal pain. Conclusion: This case illustrates the diagnostic and therapeutic complexity of metastatic malignant phyllodes tumors. Although first-line chemotherapy produced marked pulmonary tumor regression, subsequent anlotinib maintenance therapy did not prevent disease progression. In this PD-L1–positive tumor (CPS 10), sintilimab-based combination therapy yielded a marked clinical and radiographic response, supporting further investigation of ICI-based therapy in selected patients with metastatic MPT.